500 patients67,039 observations150 daysLIVE

Patient P-03285

Synthetic patientONX-7 · Day 119 · 65–74 · M · baseline S04Open companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S04
  2. Day 85 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 85.

Primary contributors, last 14 days
  • GI instability+30
  • Inflammatory activity+20
  • Treatment adherence-14
  • Nutritional resilience-7
  • Toxicity+6

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    62%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 90
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 73 and rising
      • WearableSleep 5.7 h, below personal baseline
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 43/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Autonomic recovery 45
      • WearableResting HR 73 bpm
      • WearableShort sleep window
    • Inflammatory signalling 25
      • BloodInflammatory load index 63
    • Drug metabolism and exposure 20
      • BloodToxicity index 43
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 1.9 · butyrate capacity 43/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    47 ms
    Sleep
    5.4 h
    Steps
    7,382
    Resting HR
    69 bpm
    Daily log: GI score 73, nutritional resilience 40, adherence 73.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0312046%S1461
    P-0337945%S12GI-04improved51
    P-0345144%S0862
    P-0300442%S0356
    P-0322542%S19GI-04improved50
    P-0328040%S1357
    P-0309937%S17CR-01improved55
    P-0302136%S1557
    P-0303136%S16CR-01improved49
    P-0329236%S1462
    P-0337836%S1059
    P-0338236%S01GI-04improved56